PL2201012T3 - Pochodne pirolo[2,3-d]pirymidyny jako inhibitory kinazy białkowej b - Google Patents
Pochodne pirolo[2,3-d]pirymidyny jako inhibitory kinazy białkowej bInfo
- Publication number
- PL2201012T3 PL2201012T3 PL08806741T PL08806741T PL2201012T3 PL 2201012 T3 PL2201012 T3 PL 2201012T3 PL 08806741 T PL08806741 T PL 08806741T PL 08806741 T PL08806741 T PL 08806741T PL 2201012 T3 PL2201012 T3 PL 2201012T3
- Authority
- PL
- Poland
- Prior art keywords
- pyrrolo
- inhibitors
- protein kinase
- pyrimidin derivatives
- pyrimidin
- Prior art date
Links
- JJTNLWSCFYERCK-UHFFFAOYSA-N 7h-pyrrolo[2,3-d]pyrimidine Chemical class N1=CN=C2NC=CC2=C1 JJTNLWSCFYERCK-UHFFFAOYSA-N 0.000 title 1
- 239000003197 protein kinase B inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97919207P | 2007-10-11 | 2007-10-11 | |
| US4786208P | 2008-04-25 | 2008-04-25 | |
| PCT/GB2008/050925 WO2009047563A1 (en) | 2007-10-11 | 2008-10-09 | Pyrrolo [2, 3 -d] pyrimidin derivatives as protein kinase b inhibitors |
| EP08806741.8A EP2201012B1 (en) | 2007-10-11 | 2008-10-09 | Pyrrolo[2,3-d]pyrimidin derivatives as protein kinase b inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2201012T3 true PL2201012T3 (pl) | 2014-11-28 |
Family
ID=40251789
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL08806741T PL2201012T3 (pl) | 2007-10-11 | 2008-10-09 | Pochodne pirolo[2,3-d]pirymidyny jako inhibitory kinazy białkowej b |
Country Status (43)
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
| WO2007125321A2 (en) | 2006-04-25 | 2007-11-08 | Astex Therapeutics Limited | Purine and deazapurine derivatives as pharmaceutical compounds |
| WO2008018642A2 (en) * | 2006-08-10 | 2008-02-14 | Oncotherapy Science, Inc. | Genes and polypeptides relating to breast cancers |
| PL2201012T3 (pl) | 2007-10-11 | 2014-11-28 | Astrazeneca Ab | Pochodne pirolo[2,3-d]pirymidyny jako inhibitory kinazy białkowej b |
| WO2011002772A1 (en) * | 2009-06-29 | 2011-01-06 | Oncotherapy Science, Inc. | Imidazopyridine derivatives and pbk inhibitors containing the same |
| GB201020161D0 (en) | 2010-11-26 | 2011-01-12 | Almac Discovery Ltd | Pharmaceutical compounds |
| EP2651417B1 (en) | 2010-12-16 | 2016-11-30 | Calchan Limited | Ask1 inhibiting pyrrolopyrimidine derivatives |
| JP6100700B2 (ja) | 2011-01-11 | 2017-03-22 | ノバルティス アーゲー | 組合せ |
| EP2694056B1 (en) * | 2011-04-01 | 2019-10-16 | AstraZeneca AB | Therapeutic treatment |
| PH12014500943A1 (en) * | 2011-11-30 | 2014-06-30 | Astrazeneca Ab | Combination treatment of cancer |
| AU2013204533B2 (en) * | 2012-04-17 | 2017-02-02 | Astrazeneca Ab | Crystalline forms |
| MA38287B1 (fr) | 2013-01-23 | 2018-08-31 | Astrazeneca Ab | Nouveaux dérivés aminopyrazine pour le traitement ou la prévention du cancer |
| EP2815749A1 (en) | 2013-06-20 | 2014-12-24 | IP Gesellschaft für Management mbH | Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern |
| CN105764501A (zh) | 2013-07-26 | 2016-07-13 | 现代化制药公司 | 改善比生群治疗效益的组合物 |
| JP6295578B2 (ja) * | 2013-09-30 | 2018-03-20 | 凸版印刷株式会社 | 反応容器、核酸解析装置、および核酸解析方法 |
| ES3063787T3 (en) * | 2013-10-01 | 2026-04-20 | Novartis Ag | Composition comprising a 17 a-hydroxylase/c17,20 lyase (cyp17a1) inhibitor and an akt inhibitor |
| SI3105218T1 (sl) | 2014-02-13 | 2019-11-29 | Incyte Corp | Ciklopropilamini kot inhibitorji LSD1 |
| US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| EP3105219B9 (en) | 2014-02-13 | 2018-10-03 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| MX373103B (es) | 2014-02-13 | 2020-04-17 | Incyte Holdings Corp | Ciclopropilaminas como inhibidores de desmetilasa específica de lisina 1 (lsd1). |
| RU2674027C2 (ru) * | 2014-05-28 | 2018-12-04 | Астразенека Аб | Способ получения AZD5363 (варианты) и применяемое в нем новое промежуточное соединение |
| TWI687419B (zh) | 2014-07-10 | 2020-03-11 | 美商英塞特公司 | 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪 |
| WO2016007727A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| TW201613925A (en) | 2014-07-10 | 2016-04-16 | Incyte Corp | Imidazopyrazines as LSD1 inhibitors |
| EP3277689B1 (en) | 2015-04-03 | 2019-09-04 | Incyte Corporation | Heterocyclic compounds as lsd1 inhibitors |
| LT3334709T (lt) | 2015-08-12 | 2025-03-10 | Incyte Holdings Corporation | Lsd1 inhibitoriaus druskos |
| TW201726140A (zh) | 2015-09-17 | 2017-08-01 | 瑞典商阿斯特捷利康公司 | 治療癌症之新型生物標記及方法 |
| JP6999574B2 (ja) | 2016-04-22 | 2022-01-18 | インサイト・コーポレイション | Ｌｓｄ１阻害剤の製剤 |
| WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
| IL320609A (en) | 2019-08-26 | 2025-07-01 | Arvinas Operations Inc | Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents |
| CA3158321A1 (en) | 2019-11-04 | 2021-05-14 | Astrazeneca Ab | Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies |
| TWI908780B (zh) * | 2020-03-17 | 2025-12-21 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合二環類衍生物、其製備方法及其在醫藥上的應用 |
| EP4271678A1 (en) * | 2021-01-04 | 2023-11-08 | Teva Pharmaceuticals International GmbH | Solid state forms of capivasertib and process for preparation thereof |
| CN116925080B (zh) * | 2022-03-29 | 2025-12-12 | 杭州健崃生物科技有限公司 | 作为Akt蛋白激酶抑制剂的化合物及其制备方法和用途 |
| IL315848A (en) | 2022-03-31 | 2024-11-01 | Astrazeneca Ab | Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in combination with an AKT inhibitor for cancer treatment |
| CN114601836B (zh) * | 2022-04-12 | 2022-12-06 | 四川大学华西医院 | 一种akt抑制剂在制备治疗乳腺癌的药物中的应用 |
| WO2024083716A1 (en) | 2022-10-17 | 2024-04-25 | Astrazeneca Ab | Combinations of a serd for the treatment of cancer |
| EP4615431A1 (en) | 2022-11-11 | 2025-09-17 | Astrazeneca AB | Combination therapies for the treatment of cancer |
| CN120202006A (zh) | 2022-11-15 | 2025-06-24 | 阿斯利康(瑞典)有限公司 | 卡帕塞替尼和维奈托克的治疗组合 |
| AU2024279893A1 (en) | 2023-05-26 | 2026-01-22 | Astrazeneca Ab | Pharmaceutical compositions |
| EP4719399A1 (en) | 2023-06-02 | 2026-04-08 | Arvinas Operations, Inc. | Combinations of estrogen receptor degraders and akt inhibitors |
| TW202533828A (zh) | 2024-02-22 | 2025-09-01 | 瑞典商阿斯特捷利康公司 | Ａｋｔ抑制劑、ｂｃｌ－２抑制劑、及抗ｃｄ２０抗體之治療組合 |
| WO2025238662A1 (en) * | 2024-05-15 | 2025-11-20 | Msn Laboratories Private Limited, R&D Center | Improved process for the preparation of 4-amino-n-[(1s)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4-piperidinecarboxamide and its salts |
| WO2026057582A1 (en) | 2024-09-10 | 2026-03-19 | Astrazeneca Ab | Therapeutic combinations of an akt inhibitor, a bcl-2 inhibitor, and a glucocorticoid |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE637271A (pl) | 1963-04-04 | 1900-01-01 | ||
| GB9312853D0 (en) | 1993-06-22 | 1993-08-04 | Euro Celtique Sa | Chemical compounds |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| BR9707495A (pt) | 1996-02-13 | 1999-07-27 | Zeneca Ltd | Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente |
| US6291455B1 (en) | 1996-03-05 | 2001-09-18 | Zeneca Limited | 4-anilinoquinazoline derivatives |
| JP2001519766A (ja) | 1996-04-03 | 2001-10-23 | メルク エンド カンパニー インコーポレーテッド | ファルネシルタンパク質トランスフェラーゼの阻害剤 |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| DE69837529T2 (de) | 1997-02-12 | 2007-07-26 | Electrophoretics Ltd., Cobham | Proteinmarker für lungenkrebs und deren verwendung |
| US6432947B1 (en) | 1997-02-19 | 2002-08-13 | Berlex Laboratories, Inc. | N-heterocyclic derivatives as NOS inhibitors |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| ID24300A (id) | 1997-08-05 | 2000-07-13 | Pfizer Prod Inc | 4-AMINOPIROL(3,2-d)PIRIMIDIN SEBAGAI ANTAGONIS-ANTAGONIS RESEPTOR NEUROPEPTIDA Y |
| US6162804A (en) | 1997-09-26 | 2000-12-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| CA2333770A1 (en) | 1998-06-04 | 1999-12-09 | Abbott Laboratories | Cell adhesion-inhibiting antinflammatory compounds |
| PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| US6262066B1 (en) | 1998-07-27 | 2001-07-17 | Schering Corporation | High affinity ligands for nociceptin receptor ORL-1 |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| SK288365B6 (sk) | 1999-02-10 | 2016-07-01 | Astrazeneca Ab | Medziprodukty pre chinazolínové deriváty ako inhibítory angiogenézy |
| WO2000075145A1 (en) | 1999-06-03 | 2000-12-14 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| CZ301689B6 (cs) | 1999-11-05 | 2010-05-26 | Astrazeneca Ab | Derivát chinazolinu a farmaceutický prostredek, který ho obsahuje |
| US7160890B2 (en) | 1999-12-02 | 2007-01-09 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
| SI1255752T1 (sl) | 2000-02-15 | 2007-12-31 | Pharmacia & Upjohn Co Llc | S pirolom substituirani zaviralci 2-indolinon protein kinaza |
| NZ522074A (en) | 2000-05-31 | 2004-06-25 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| IL152771A0 (en) | 2000-06-26 | 2003-06-24 | Pfizer Prod Inc | PYRROLO(2,3-d) PYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE AGENTS |
| IL153484A0 (en) | 2000-07-07 | 2003-07-06 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors |
| CN1255392C (zh) | 2000-07-07 | 2006-05-10 | 安吉奥金尼药品有限公司 | 作为血管生成抑制剂的秋水仙醇衍生物 |
| BR0113585A (pt) | 2000-08-31 | 2003-07-29 | Hoffmann La Roche | Derivados quinazolina como antagonistas adrenérgicos alfa-1 |
| US6673802B2 (en) | 2000-12-01 | 2004-01-06 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
| AP1893A (en) | 2000-12-01 | 2008-09-23 | Osi Pharm Inc | Compounds specific to adenosine A1, A2A and A3 receptor and uses thereof |
| US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| JP2004532234A (ja) * | 2001-04-27 | 2004-10-21 | バーテックス ファーマシューティカルズ インコーポレイテッド | トリアゾール由来キナーゼインヒビターおよびその使用 |
| AU2003235741B8 (en) | 2002-01-07 | 2009-01-15 | Eisai R&D Management Co., Ltd. | Deazapurines and uses thereof |
| TW200403058A (en) | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
| DK1522314T3 (da) | 2002-06-26 | 2014-05-26 | Ono Pharmaceutical Co | Midler for sygdomme forårsaget af vaskulær sammentrækning eller udvidelse |
| US20040138238A1 (en) | 2002-08-08 | 2004-07-15 | Dhanoa Dale S. | Substituted aminopyrimidine compounds as neurokinin antagonists |
| US20030139427A1 (en) | 2002-08-23 | 2003-07-24 | Osi Pharmaceuticals Inc. | Bicyclic pyrimidinyl derivatives and methods of use thereof |
| AU2003265636A1 (en) | 2002-09-06 | 2004-03-29 | Smithkline Beecham Corporation | Pyrrolo(2, 3-d)pyrimidine-4-yl and purin-6-yl urea compounds |
| JP4796301B2 (ja) | 2002-11-08 | 2011-10-19 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | テクネチウム−９９ｍ及びレニウムで標識した小型作用剤及び組織、臓器及び腫瘍の画像化方法 |
| JP4279784B2 (ja) | 2002-12-04 | 2009-06-17 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | １，３−ジヒドロ−イミダゾール縮合環化合物 |
| EP1444982A1 (de) | 2003-02-06 | 2004-08-11 | Merckle Gmbh | Verwendung von Purinderivaten als selektive Kinase-Inhibitoren |
| MXPA05009722A (es) | 2003-03-10 | 2006-03-09 | Schering Corp | Inhibidores heterociclicos de cinasa: metodos de uso y sintesis. |
| EP1615926A1 (en) | 2003-04-21 | 2006-01-18 | Ustav Organicke Chemie A Biochemie Akademie Ved Ceske Republiky | (purin-6-yl) amino acid and production method thereof |
| FR2856685B1 (fr) | 2003-06-25 | 2005-09-23 | Merck Sante Sas | Derives de thiazolylpiperidine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent |
| EP1663204B1 (en) | 2003-08-29 | 2014-05-07 | Exelixis, Inc. | C-kit modulators and methods of use |
| WO2005044181A2 (en) | 2003-09-09 | 2005-05-19 | Temple University-Of The Commonwealth System Of Higher Education | Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors |
| TW200526626A (en) | 2003-09-13 | 2005-08-16 | Astrazeneca Ab | Chemical compounds |
| CA2546754A1 (en) | 2003-11-21 | 2005-06-09 | Array Biopharma Inc. | Akt protein kinase inhibitors |
| WO2005063704A1 (ja) | 2003-12-25 | 2005-07-14 | Ono Pharmaceutical Co., Ltd. | アゼチジン環化合物およびその医薬 |
| MXPA06010520A (es) * | 2004-03-30 | 2007-03-26 | Chiron Corp | Derivados de tiofeno sustituidos como agentes anticancerosos. |
| WO2005117909A2 (en) * | 2004-04-23 | 2005-12-15 | Exelixis, Inc. | Kinase modulators and methods of use |
| MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
| UY29177A1 (es) * | 2004-10-25 | 2006-05-31 | Astex Therapeutics Ltd | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos |
| CA2590961C (en) * | 2004-12-28 | 2013-11-26 | Exelixis, Inc. | [1h-pyrazolo[3,4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases |
| FR2880626B1 (fr) | 2005-01-13 | 2008-04-18 | Aventis Pharma Sa | Derives de la purine, compositions les contenant et utilisation |
| FR2880540B1 (fr) | 2005-01-13 | 2008-07-11 | Aventis Pharma Sa | Utilisation de derives de la purine comme inhibiteurs de la proteine hsp90 |
| US7423043B2 (en) | 2005-02-18 | 2008-09-09 | Lexicon Pharmaceuticals, Inc. | 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds |
| US20060281768A1 (en) | 2005-06-10 | 2006-12-14 | Gaul Michael D | Thienopyrimidine and thienopyridine kinase modulators |
| WO2007007919A2 (en) | 2005-07-14 | 2007-01-18 | Astellas Pharma Inc. | Heterocyclic janus kinase 3 inhibitors |
| WO2007025090A2 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase |
| US20070208053A1 (en) | 2006-01-19 | 2007-09-06 | Arnold Lee D | Fused heterobicyclic kinase inhibitors |
| JP2009534454A (ja) | 2006-04-25 | 2009-09-24 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
| EP2029592A1 (en) * | 2006-04-25 | 2009-03-04 | Astex Therapeutics Limited | Pharmaceutical compounds |
| WO2007125321A2 (en) | 2006-04-25 | 2007-11-08 | Astex Therapeutics Limited | Purine and deazapurine derivatives as pharmaceutical compounds |
| WO2007125315A2 (en) | 2006-04-25 | 2007-11-08 | Astex Therapeutics Limited | Pharmaceutical compounds |
| EP2037931A2 (en) | 2006-04-25 | 2009-03-25 | Astex Therapeutics Limited | Pharmaceutical combinations of pk inhibitors and other active agents |
| AR064415A1 (es) | 2006-12-21 | 2009-04-01 | Cancer Rec Tech Ltd | Derivados de pirrolo-piperidinas y purinas,composiciones farmaceuticas que los contienen y usos en trastornos y/o enfermedades mediadas por pka y pkb. |
| AR064416A1 (es) | 2006-12-21 | 2009-04-01 | Cancer Rec Tech Ltd | Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas. |
| AU2007338754A1 (en) | 2006-12-21 | 2008-07-03 | Vertex Pharmaceuticals Incorporated | 5-cyan0-4- (pyrrolo [2, 3B] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors |
| PL2201012T3 (pl) | 2007-10-11 | 2014-11-28 | Astrazeneca Ab | Pochodne pirolo[2,3-d]pirymidyny jako inhibitory kinazy białkowej b |
-
2008
- 2008-10-09 PL PL08806741T patent/PL2201012T3/pl unknown
- 2008-10-09 RS RS20140457A patent/RS53552B1/sr unknown
- 2008-10-09 TW TW097139021A patent/TWI453021B/zh active
- 2008-10-09 UY UY31384A patent/UY31384A1/es not_active Application Discontinuation
- 2008-10-09 PT PT88067418T patent/PT2201012E/pt unknown
- 2008-10-09 MY MYPI2010001617A patent/MY150059A/en unknown
- 2008-10-09 WO PCT/GB2008/050925 patent/WO2009047563A1/en not_active Ceased
- 2008-10-09 KR KR1020107010107A patent/KR101494734B1/ko active Active
- 2008-10-09 NZ NZ585261A patent/NZ585261A/en unknown
- 2008-10-09 MX MX2010003927A patent/MX2010003927A/es active IP Right Grant
- 2008-10-09 BR BRPI0818533A patent/BRPI0818533B8/pt active IP Right Grant
- 2008-10-09 AU AU2008309383A patent/AU2008309383B2/en active Active
- 2008-10-09 EA EA201000552A patent/EA018512B1/ru not_active IP Right Cessation
- 2008-10-09 HR HRP20140807AT patent/HRP20140807T1/hr unknown
- 2008-10-09 ES ES08806741.8T patent/ES2522365T3/es active Active
- 2008-10-09 DK DK08806741.8T patent/DK2201012T3/da active
- 2008-10-09 SI SI200831281T patent/SI2201012T1/sl unknown
- 2008-10-09 ME MEP-2014-102A patent/ME01999B/me unknown
- 2008-10-09 CA CA2701057A patent/CA2701057C/en active Active
- 2008-10-09 JP JP2010528485A patent/JP4705695B2/ja active Active
- 2008-10-09 EP EP08806741.8A patent/EP2201012B1/en active Active
- 2008-10-09 CN CN200880116651XA patent/CN101861321B/zh active Active
- 2008-10-10 PE PE2008001748A patent/PE20090964A1/es active IP Right Grant
- 2008-10-10 CL CL2008003023A patent/CL2008003023A1/es unknown
- 2008-10-10 PE PE2012002041A patent/PE20130152A1/es not_active Application Discontinuation
- 2008-10-10 AR ARP080104450A patent/AR068846A1/es active IP Right Grant
- 2008-10-10 US US12/249,477 patent/US8101623B2/en active Active
- 2008-10-11 SA SA8290625A patent/SA08290625B1/ar unknown
-
2010
- 2010-03-25 IL IL204721A patent/IL204721A/en active IP Right Grant
- 2010-03-31 ZA ZA2010/02318A patent/ZA201002318B/en unknown
- 2010-04-09 NI NI201000050A patent/NI201000050A/es unknown
- 2010-04-09 CR CR11359A patent/CR11359A/es unknown
- 2010-04-09 CU CU20100062A patent/CU23886B1/es active IP Right Grant
- 2010-04-09 GT GT201000082A patent/GT201000082A/es unknown
- 2010-04-09 HN HN2010000653A patent/HN2010000653A/es unknown
- 2010-04-09 DO DO2010000103A patent/DOP2010000103A/es unknown
- 2010-05-06 CO CO10054272A patent/CO6270328A2/es active IP Right Grant
-
2011
- 2011-03-09 JP JP2011051117A patent/JP5330430B2/ja active Active
- 2011-12-13 US US13/324,191 patent/US20120190679A1/en not_active Abandoned
-
2014
- 2014-08-28 CY CY20141100689T patent/CY1116929T1/el unknown
-
2015
- 2015-02-19 US US14/626,303 patent/US9492453B2/en active Active
-
2016
- 2016-11-15 US US15/351,481 patent/US10059714B2/en active Active
-
2018
- 2018-07-06 US US16/028,979 patent/US10654855B2/en active Active
-
2020
- 2020-04-07 US US16/841,820 patent/US11236095B2/en active Active
-
2021
- 2021-12-16 US US17/644,654 patent/US11760760B2/en active Active
-
2023
- 2023-08-04 US US18/365,286 patent/US12252495B2/en active Active
-
2024
- 2024-11-12 HU HUS2400038C patent/HUS2400038I1/hu unknown
- 2024-11-12 FI FIC20240039C patent/FIC20240039I1/fi unknown
- 2024-11-12 NL NL301299C patent/NL301299I2/nl unknown
- 2024-11-13 LT LTPA2024532C patent/LTC2201012I2/lt unknown
- 2024-11-18 NO NO2024050C patent/NO2024050I1/no unknown
- 2024-11-18 CY CY2024030C patent/CY2024030I2/el unknown
- 2024-12-02 FR FR24C1046C patent/FR24C1046I2/fr active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2400038I1 (hu) | Pirrolo[2,3-d]primidin származékok, mint protein kináz B inhibitorok | |
| IL278119B (en) | Disubstituted pyrazolo[5.1–a]pyrimidine compounds as trk kinase inhibitors | |
| SI1893612T1 (sl) | Pirolo b piridin derivati kot protein kinazni inhibitorji | |
| HUE041382T2 (hu) | Pirrolo[2,3-d]pirimidin származékok janus-kináz inhibitorként | |
| ZA200809796B (en) | Pyrazolo [1,5-A]pyrimidines as CDK inhibitors | |
| ZA201101701B (en) | Pyrrolo[2,3-d]pyrimidine compounds | |
| ZA201200982B (en) | Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors | |
| ZA201003050B (en) | [1h- pyrazolo [3, 4-b] pyridine-4-yl] -phenyle or pyridin-2-yle derivatives as protein kinase c-theta | |
| IL207224A0 (en) | Pyrrolo [2,3-d] pyrimidines and use thereof as tyrosine kinase inhibitors | |
| IL217798A0 (en) | Pyrrolo [1,2-b]pyridazine derivatives as janus kinase inhibitors | |
| ZA201004368B (en) | Pyrazolo [1,5-a] pyrimidines useful as jak2 inhibitors | |
| ZA200803173B (en) | Pyrazolo [4,3-d] Pyrimidin-5-yl) Derivative used as PDE5 Inhibitors | |
| HK1112231A (en) | Pyrazolo [1,5-a] pyrimidines as protein kinase inhibitors | |
| HK1160846A (en) | [1, 2, 4] triazolo [1, 5 -a] pyridines as kinase inhibitors |